Lenvatinib Mesylate Intermediate CAS 205448-65-3 Purity> 98,0% (HPLC) Pabrik
Ruifu Kimia Supply Lenvatinib Mesylate panengah Jeung Purity High
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Métil 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Métil 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimétil-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Métil 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Ngaran Kimia | Métil 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate |
sinonim | 1,4-Dihydro-7-Methoxy-4-Oxo-6-Quinolinecarboxylic Asam Métil Éster;7-Methoxy-4-Oxo-1,4-Dihydro-Quinoline-6-Carboxylic Asam Métil Éster;Lenvatinib panengah 3 |
Nomer CAS | 205448-65-3 |
Nomer CAT | RF-PI1973 |
Status Saham | Dina Stock, Kapasitas Produksi 50 MT / Taun |
Formula Molekul | C12H11NO4 |
Beurat Molekul | 233.22 |
Titik didih | 421,0 ± 45,0 ℃ |
Kapadetan | 1,267±0,060 g/cm3 |
merek | Kimia Ruifu |
Barang | spésifikasi |
Penampilan | Pareum-bodas nepi ka bubuk konéng |
Purity / Métode Analisis | > 98,0% (HPLC) |
Leungitna dina Drying | <1,00% |
Résidu on Ignition | <0,50% |
Total Kotoran | <2.00% |
H-NMR | Conforms kana Struktur |
Standar tés | Standar Perusahaan |
Pamakéan | Panganteur Farmasi |
Bungkusan: Botol, kantong Aluminium foil, 25kg / Karton Drum, atawa nurutkeun sarat customer urang
Kaayaan Panyimpenan:Simpen dina wadah anu disegel dina tempat anu tiis sareng garing;Ngajaga tina cahaya sareng Uap
Métil 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate (CAS: 205448-65-3) mangrupikeun perantara Lenvatinib Mesylate (CAS: 857890-39-2).Lenvatinib, dijual kalayan nami merek Lenvima antara anu sanésna, mangrupikeun ubar anti-kanker pikeun pengobatan sababaraha jinis kanker tiroid sareng kanker sanésna ogé.Diwangun ku Eisai Co.Lenvatinib disatujuan (saprak 2015) pikeun pengobatan kanker tiroid anu dibédakeun boh kumbuh sacara lokal atanapi métastatik, progresif, sareng henteu ngaréspon kana perlakuan sareng iodin radioaktif (radioiodin).Dina Méi 2016, Administrasi Pangan sareng Narkoba AS (FDA) nyatujuan éta (dina kombinasi sareng everolimus) pikeun pengobatan carcinoma sél ginjal maju saatos hiji terapi anti-angiogenik sateuacana.Ubar ieu ogé disatujuan di AS sareng di Uni Éropa pikeun karsinoma hépatoselular anu teu tiasa dipiceun sacara bedah dina pasien anu henteu acan nampi terapi kanker ku sungut atanapi suntikan.